Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

(2021) John H. Baird et al.   Blood Advances

Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma

(2021) Paolo Strati et al.   BLOOD

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

(2020) Max S. Topp et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

(2020) Paolo Strati et al.   Blood Advances

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

(2020) Tania Jain et al.   Blood Advances

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

(2020) Marcela V Maus et al.   Journal for ImmunoTherapy of Cancer

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells

(2019) Philipp Karschnia et al.   BLOOD

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome

(2016) Bita Shakoory et al.   CRITICAL CARE MEDICINE

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

(2016) Fang Chen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Interleukin-1 in Stroke

(2016) Oluwaseun A. Sobowale et al.   STROKE

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery